Molnupiravir is the first Covid drug authorized by Drugs Controller General {India) (DCGI) for the treatment of Covid 19 infection with Sp02>93% and who have high risk of progression of the disease including hospitalization or death.

This capsule was earlier approved in United Kingdom and United States of America. Molnunat will be marketed by Natco and will be priced affordably.

Molnupiravir is the first Covid drug available in Indian market with a minimal dosage duration of 5 days with promising viral clearance. Phase 3 trials of molnupiravir has shown significant reduction in hospitalization of Covid 19 patients.